MWNA
CBAY

Marshall Wace North America’s Cymabay Therapeutics CBAY Stock Holding History

Marshall Wace North America’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-365,866
Closed -$541K – 1558
2020
Q1 		$541K Buy
+365,866
New +$614K ﹤0.01% 740
2019
Q4 		– Sell
-8,726
Closed -$45K – 1680
2019
Q3 		$45K Sell
8,726
-14,152
-62% -$85.7K ﹤0.01% 1172
2019
Q2 		$164K Sell
22,878
-99,914
-81% -$1.13M ﹤0.01% 1053
2019
Q1 		$1.63M Buy
122,792
+116,135
+1,745% +$1.24M 0.01% 559
2018
Q4 		$52K Buy
+6,657
New +$63.4K ﹤0.01% 1243
2017
Q3 		– Sell
-40,416
Closed -$242K – 1559
2017
Q2 		$242K Buy
+40,416
New +$172K ﹤0.01% 1194

Other funds holding CBAY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Marshall Wace North America's CBAY Position: Q2 2020 in Review

Marshall Wace North America sold out of Cymabay Therapeutics (CBAY) in Q2 2020, closing a stake of 365,866 shares — an estimated $541K sold.

Marshall Wace North America first reported a position in CBAY in Q2 2017 and held it in 6 quarters. The position peaked at $1.63M in Q1 2019. 114 funds tracked by Wall St. Rank hold CBAY as of Q2 2020.

  • Marshall Wace North America reported no remaining Cymabay Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Marshall Wace North America sold 365,866 Cymabay Therapeutics shares in Q2 2020, an estimated $541K.
  • Marshall Wace North America first reported a position in Cymabay Therapeutics in Q2 2017 and held it in 6 quarters.
  • Marshall Wace North America's Cymabay Therapeutics position peaked at $1.63M in Q1 2019.
  • 114 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2020.

Based on Marshall Wace North America's 13F filing for Q2 2020, filed 13 Aug 2020.